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Abstract 
  
Long-chain acyl-CoA synthetases are a family of enzymes responsible for catalyzing the 
reaction converting long chain fatty acids to fatty acyl-CoA. ACSL4, a specific member of this 
family, plays a role in eicosanoid metabolism and has been found to be associated with liver 
diseases including non-alcoholic fatty liver disease and hepatocellular carcinoma. In order to 
study ACSL4 in the context of hepatic lipid metabolism, a murine liver-specific Acsl4 knockout 
(Acsl4 L -/-) was developed and characterized in our lab. Based on a previous experiment in our 
lab, we hypothesized that Acsl4 L -/- would cause a defect in beta adrenergic signaling. In order to 
test this hypothesis, we conducted experiments to determine the effects of various treatments on 
the expression of fatty acid oxidation-related genes in both knockout and control hepatocytes. 
Treatments with fatty acids caused increases in expression of several fatty acid oxidation-related 
genes in both knockout and control hepatocytes. Hormone treatments did not cause anticipated 
increases in expression of fatty acid oxidation-related genes in several of the control groups. 
Because of this we were not able to make conclusions about the effects of the knockout. These 
results indicated that Acsl4 L -/- did not cause a defect in beta adrenergic signaling.  
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Chapter I. Introduction 
 
1.1 Liver and Lipid Metabolism 
 The liver is perhaps the most important organ when it comes to lipid metabolism, acting 
as the main site for fatty acid (FA) synthesis, fatty acid oxidation, complex lipid synthesis, and 
very low-density lipoprotein (VLDL) production.  The liver acts as a mediator for fat metabolism 
to meet the energy requirements of the rest of the body.  These metabolic pathways are 
controlled by various enzyme interactions and regulated by the liver under different hormonal 
and physiological conditions.  
 Lipid metabolism starts with the digestion and absorption of dietary fats. In the mouth, 
lipids are first broken down by lingual lipases and further processed in the stomach and 
duodenum where dietary fats are emulsified with help from bile acids secreted from the 
gallbladder. Lipases secreted from the pancreas further digest lipids into free FA and 
monoacylglycerol to be absorbed by enterocytes. Within the enterocyte, triacylglerol (TAG) 
molecules are resynthesized and repackaged along with cholesterol esters (CE), phospholipids 
(PL), lipoproteins, and fat-soluble vitamins into chylomicron lipoproteins that pass into lacteals 
that eventually enter circulation. Peripheral tissues hydrolyze TAG from chylomicrons via 
lipoprotein lipase to obtain FA while remnant chylomicrons and other lipoproteins are taken up 
by the liver. The liver incorporates the components of remnant lipoproteins particles into various 
metabolic pathways.  
Long-chain FAs are activated by the long chain acyl-CoA synthetase (ACSL) enzyme 
family, which converts long chain FAs into long chain fatty acyl-CoAs and shuttles them into 
different metabolic pathways.1 Depending on energy status, activated FAs can enter synthetic 
pathways such as de novo lipogenesis, TAG synthesis, and phospholipid synthesis. TAG 
synthesis is initiated by ACSLs, with glycerol-3-phosphate acyltransferase (GPAT) catalyzing 
the formation of TAG by esterifying glycerol-3-phosphate with acyl-CoA. Acetyl-CoA 
carboxylase (ACC) catalyzes the conversion of acetyl-CoA to malonyl-CoA and is a rate-
limiting enzyme of de novo lipogenesis. ACC activity is inhibited under low energy conditions. 
Elongation of malonyl-CoA for FA synthesis is catalyzed by fatty acid synthetase (FAS). These 
processes are highly regulated by insulin and glucagon signals that regulate appropriate pathways 
during fed and fasting conditions respectively. As the major lipid metabolism center of the body, 
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the liver also serves as the main distribution center. It exports lipids, TAG, CE, and 
phospholipids by producing and secreting VLDL for peripheral utilization of lipids and FAs. 
Hepatic concentrations of lipid and apolipoprotein B100 directly affect VLDL production and 
secretion.  
Beta-oxidation is the degradative pathway of FAs activated by ACSLs, which produces 
acetyl-CoA from fatty acyl-CoA to be used as energy production via the Krebs cycle and 
oxidative phosphorylation. The main regulated enzyme of beta-oxidation is carnitine 
palmitoyltransferase I (CPT-1), which catalyzes the entry of fatty acyl CoA into the 
mitochondria via conversion to acyl-carnitine. CPT-1 is inhibited by malonyl CoA, which is 
produced by ACC during de novo lipogenesis. Beta-oxidation is also regulated by the 
transcription factor peroxisome proliferator-activated receptor alpha (PPARa). PPARa ligand 
activation induces several genes controlling FA import including CPT-1 and several major 
enzymes within the beta-oxidation pathway including acyl-CoA dehydrogenases.2  
 
1.2 ACSL4 Gene and Protein 
 While all enzymes in the ACSL family serve the same enzymatic function, the ACSL 
isoforms vary in substrate specificity, subcellular location, and potential impact on downstream 
metabolic functions. With the exception of ACSL4, which is localized to both the plasma 
membrane and cytosol, most of the ACSL isoforms are membrane associated. 3 Accurate 
methods for measuring enzymatic activity for individual ACSL isoforms have not been well 
established due to non-specificity of ACSL inhibitors. It is still unclear how each isoform’s 
distinct structure and subcellular location affect function and activity. This study aims to 
investigate the effects of a liver-specific ACSL4 knock out (ACSL4 L -/-) mouse model to study 
the role of ACSL4 in hepatic lipid metabolism. 
 ACSL4 is a member of the ACS family that is encoded by the Acsl4 gene located on the 
X-chromosome adjacent to the Col4a5 gene at Xq23 4. The ACSL4 protein contains 711 amino 
acids with an AMP-dependent synthetase domain and an AMP-binding domain. Alternative 
splicing produces two possible forms of the ACSL4 isoform. ACSL4 variant 1 is a 75 kDa 
protein located within the cytosol. ACSL4 variant 2 is a 79 kDa protein that contains additional 
hydrophobic amino acids at the N-terminus that contribute to membrane localization in both the 
outer mitochondrial membrane and the endoplasmic reticulum.5   
3		
1.3 ACSL4 Abnormalities and Human Disease 
Sequence abnormalities and sequence deletions surrounding the Acsl4 gene have been 
associated with several conditions including elliptocytosis, mental retardation, and Alport 
syndrome. Alport syndrome is an X-linked condition that is characterized by a large deletion of 
the Xq22.3-23 (including the Acsl4 gene) region of the X-chromosome.  Its symptoms include 
progressive renal failure, hearing loss, and vision loss. High Acsl4 expression in specific regions 
of the brain, including the cerebellum and hippocampus, and its deficiencies associated with 
mental retardation suggest that the enzyme may play an important role in brain development.6 
Investigations of Acsl4 expression during mouse development showed high levels of expression 
in mice embryos and newborn brains.7  
ACSL4 dysregulation has also been studied in the context of hepatic lipid dysfunction 
associated with non-alcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma. Studies 
using CLOCK-deficient mouse models found that reduced Acsl4 and Fabp1 expression was 
associated with reduced steatosis on a high fat diet.8 This suggests that ACSL4 may play a role in 
the development of hepatosteatosis and circadian controlled lipid metabolism. In human studies, 
researchers identified polymorphisms in Acsl4 that were related to liver fat content. Higher 
hepatic lipid content of NAFLD patients, along with hyperinsulinemia and obesity, were 
associated with the expression of a rare ACSL4 rs7887981 allele.9 ACSL4 was also found to be 
involved in hepatocellular carcinoma development.10 Several human hepatoma cell lines, 
including Hep3B and HepG2, have exhibited high ACSL4 expression.11 In patients, ACSL4 has 
been found to be up-regulated (between 2.3 and 27.5-fold) in hepatocellular carcinoma compared 
to adjacent non-cancerous tissue.11 These findings suggest that ACSL4 expression may 
contribute to dysregulation in hepatic lipid metabolism associated with both cancer and steatosis.  
 
1.4 ACSL4 Tissue and Substrate Preferences 
 As mentioned before, each ACS isoform has a specific FA substrate preference and a 
unique distribution across tissues in the body. Kinetic analyses have shown that ACSL4 has a 
preference for polyunsaturated FAs, with lower affinities for saturated and mono, di-, and tri-
unsaturated FAs. The enzyme preferentially utilizes arachidonate and eicosapentaenoate as 
substrates over the other 8-12 carbon saturated FAs and 14-22 carbon unsaturated FAs examined 
in the analyses.6 ACSL4 is present in the brain and steroidogenic tissues. RNA analyses have 
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revealed the presence of Acsl4 transcripts in the adrenal cortex, brain, lung, ovaries, testes, and 
liver.6 Because of its preference for polyunsaturated FAs, ACSL4 may play an important role in 
eicosanoid metabolism. Arachidonate has potential to generate inflammatory products as a 
precursor to several clinically important eicosanoids and metabolites of eicosanoids.  
Cyclooxygenases metabolize arachidonate to prostaglandins and thromboxanes that mediate 
inflammation and platelet aggregation. To prevent excessive eicosanoid synthesis, free 
arachidonate is converted to arachidonoyl-CoA by ACS enzymes and re-esterified into 
phospholipids.  
 
1.5 Study Aims and Hypothesis: 
 Liver-specific ACSL4 knock out mice (ACSL4 L -/-) have been developed to further 
investigate the role of ACSL4 in hepatic lipid metabolism. Under fasting and ketogenic 
conditions, ACSL4 L -/- mice and control mice do not exhibit differences in ACS activity, serum 
TAG, or serum glucose. Ongoing studies have suggested that ACSL4 L -/- may affect 
transcriptional regulation of beta-oxidation by disrupting adrenergic signaling. Hepatic lipid 
metabolism is tightly controlled by hormone responses. Glucagon and catecholamines, such as 
norepinephrine, stimulate G-protein coupled receptors and initiate signaling cascades that 
regulate both glucose and lipid homeostasis via transcriptional regulation. Stimulation of 
adrenergic and glucagon receptors increases production of cAMP and activates protein kinase A 
(PKA). PKA phosphorylates transcription factor CREB, which induces PGC-1α gene expression. 
Acting as a coactivator, PGC-1α is recruited by transcription factors such as PPARα that bind to 
the promoter regions of FA oxidation enzyme genes to increase expression.12  
A previous study tested the effects of norepinephrine treatments on cultured primary 
hepatocytes from both control and ACSL4 L -/- mice. Results showed lowered gene expression of 
beta-oxidation genes among ACSL4 L -/- hepatocytes after treatment compared to control. 
Treatments with PKA activator 8-Br-cAMP (a long-acting derivative of cAMP) induced similar 
levels of gene expression of beta-oxidation genes in both ACSL4 L -/- and control hepatocytes 
suggesting a possible role of ACSL4 in adrenergic signaling pathway before PKA activation. 
Oleic acid, but not long chain saturated or polyunsaturated FAs, has been found to stimulate 
cAMP production and PKA activity. PKA phosphorylates SIRT1, which then deacetylates and 
activates PGC-1α to subsequently increase expression of beta-oxidation genes.13  
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Therefore, our study aimed to examine the effects of Acsl4 deletion on the expression of 
FA oxidation genes after treatments with several hormones and metabolites that promote 
oxidation and to validate the findings of the previous study. We hypothesize that after treatments 
that activate the adrenergic receptor, ACSL4 L -/- hepatocytes will exhibit lower FA oxidation 
gene expression compared to control. We also hypothesize that after oleic acid treatment, ACSL4 
L -/- hepatocytes will exhibit greater FA oxidation gene expression compared to control. Lastly, 
we hypothesize that after treatments that directly elevate intracellular cAMP levels, ACSL4 L -/- 
and control hepatocytes will have similar FA oxidation gene expression.   
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Chapter II. Methods and Materials 
 
2.1 Primary hepatocyte isolation and preparation  
 Primary hepatocytes were isolated from the livers of 3-month-old ACSL4 L -/- mice and 
floxed control littermates. Because Acsl4 is X-linked, we used male knockout mice for our 
experiments. Hepatocytes were plated at 4 X 105 cells per well in 6-well plates with William’s E. 
media (5% serum). After two hours, William’s E. media was replaced with low glucose DMEM 
(1g/L glucose, 10% fetal bovine serum, penicillin-streptomycin). Before treatments, primary 
hepatocytes of both genotypes were serum starved in low glucose DMEM (5mM glucose, 1mM 
sodium pyruvate, 1mM L-Glutamine, serum free) media using 1 ml per well for 4 hours. 
 
2.2 Primary hepatocyte hormone treatments 
 All treatments were prepared using the same glucose (5mM) DMEM media at 1 mL per 
well. Hormone solutions were added to three wells of each plate and the corresponding vehicle 
control solutions were added to the remaining three wells of each plate.  The norepinephrine 
solution was prepared at 10µM from a 10mM norepinephrine stock (dissolved in water) diluted 
in media. The 8-Br-cAMP treatment solution was prepared at 1 mM from an 80mM stock 
(dissolved in water) diluted in media. The forskolin treatment solution was prepared at 40 µM 
from a 4mM stock (dissolved in DMSO) diluted in media. The glucagon treatment solution was 
prepared at 100mM from a 1mg/mL stock (dissolved in phosphate buffered saline) diluted in 
media. All vehicle control solutions were prepared by diluting the corresponding vehicle (Table 
1) in media by the same dilution factor used for diluting the stock hormone solution. After 
incubating the hepatocytes for 1 hour, the cells were washed twice with chilled PBS and frozen 
at -80° C.  
 
2.3 Primary hepatocyte lipid treatments  
 All treatments were prepared using the same glucose (5mM) DMEM media at 1 mL per 
well. Lipid solutions were added to three wells of each plate and the corresponding vehicle 
control solutions were added to the remaining three wells of each plate.  The oleate treatment 
was prepared at 500µM from a 100mM stock (in 50% ethanol) diluted in media. The palmitate 
treatment was prepared at 500µM from a 200mM stock (in 50% ethanol) diluted in media. Both 
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stock solutions were first diluted with fatty acid free bovine serum albumin (1:25 for oleate and 
1:50 for palmitate) and allowed to complex at 37° C for 1 hour. Carnitine and serum free media 
was added to both solutions for final concentrations of 1mM carnitine and 500µM of FA. After 
treating the primary hepatocytes for 3.5 hours, the cells were washed twice with chilled PBS and 
stored at -80°C.   
 
2.4 Gene expression in ACSL4 L -/- and control primary hepatocytes 
 Before testing expression of FA oxidation genes, the liver-specific knockout of Acsl4 was 
confirmed.  RNA was extracted from both ACSL4 L -/- hepatocytes and littermate control 
hepatocytes using phenol chloroform extraction (Invitrogen TRIzol reagent). RNA concentration 
was measured by spectrophotometry and cDNA was made by reverse transcription (iScript 
cDNA synthesis kit) using 1µg of RNA. The mRNA levels of Acsl4 were quantified with real 
time PCR using ACSL4 and β-actin primers (Table 1) to determine the relative expression of 
Acsl4 compared to Actin (Biorad iTaq universal SYBR green supermix). Acsl4 expression in 
ACSL4 L -/- mice was less than 1% of control littermates, confirming the knockout. The same 
process was carried out to determine the gene expression levels of the other genes of interest 
using the corresponding forward and reverse primers (Table 2) and normalizing to Actin 
expression. For each data set generated, cycle threshold values were normalized to Actin and 
treatment control values.  
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Chapter III. Results 
 
3.1 Oleate and palmitate treatment effects on gene expression 
 To determine whether ACSL4 L -/- disrupts oleate’s signaling effects on the expression of 
beta-oxidation genes, ACSL4 L -/- and control hepatocytes were treated with oleate and palmitate. 
Two experiments were conducted using a different set of hepatocytes. RT-PCR results from 
Experiment 1 showed increased Cpt1a, Acox1, Pgc1a, and Ppara expression (relative to Actin) 
following both oleate and palmitate treatments (Figure 1). These increases in gene expression 
occurred in both ACSL4 L -/- and control hepatocytes. Experiment 2 results, with palmitate 
treatment, showed increased Cpt1a, Acox1, Ppara and Creb expression in control hepatocytes 
along with increased Acox1 and decrease Ppara expression in ACSL4 L -/- hepatocytes (Figure 2). 
Experiment 2 results, with oleate treatment, showed increased Creb expression and decreased 
Pgc-1α and Pparα expression in control hepatocytes. In ACSL4 L -/- hepatocytes, oleate treatment 
resulted in increased Creb and Acox1 expression and decreased Pgc-1α and Pparα expression.  
  
3.2 Hormone treatment effects on gene expression 
To investigate whether ACSL4 L -/- disrupts adrenergic signaling effects on beta oxidation 
gene expression, ACSL4 L -/- and control hepatocytes were treated with norepinephrine, forskolin, 
glucagon, and 8-Br-cAMP. All of these hormone treatments increase expression of fatty acid 
oxidation-related genes by increasing intracellular cAMP (Figure 5). RT-PCR results from 
Experiment 1 showed increased Pgc1a, Cpt1a, and Ppara expression following norepinephrine 
treatment only in control hepatocytes (Figure 3A). With 8-Br-cAMP treatment, Pgc1a 
expression increased only in ACSL4 L -/- hepatocytes. There was also lowered Cpt1a and Ppara 
expression among all ACSL4 L -/- hepatocytes in the 8-Br-cAMP study compared to control 
(Figure 3B). After forskolin treatment, Ppar expression decreased only in ACSL4 L -/- hepatocytes 
(Figure 3C). After glucagon treatment, Pepck expression increased only in control hepatocytes 
(Figure 3C). There was also lowered Pdk4 expression in ACSL4 L -/- hepatocytes compared to 
control following glucagon treatment. 
After correcting the defects of Experiment 1, the experiment was repeated. Experiment 2 
results showed different patterns of gene expression after treating hepatocytes with 
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norepinephrine and 8-Br-cAMP treatments. Unlike in Experiment 1, norepinephrine treatment 
increased Pgc1a expression in both ACSL4 L -/- and control hepatocytes and increased Cpt1a 
expression in only ACSL4 L -/- hepatocytes. Cpt1a and Ppara expression decreased among control 
hepatocytes following norepinephrine treatment (Figure 4A). Treatment with 8-Br-cAMP only 
affected Pgc1a expression, with increased expression in both control and ACSL4 L -/- hepatocytes 
(Figure 4B). Following forskolin treatment, only Pgc1a expression increased in control 
hepatocytes while only Cpt1a expression decreased in ACSL4 L -/- hepatocytes (Figure 4C). 
Following glucagon treatment, both Pepck and G6pase expression increased in control 
hepatocytes (Figure 4D).  Unlike in Experiment 1, G6pase expression also increased in ACSL4 L -
/- hepatocytes following glucagon treatment.  
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Chapter IV. Discussion 
 
4.1 Adjustments to Methods and Materials 
 Experiment 1 produced gene expression data that were inconsistent with the expected 
treatment effects. The data also exhibited high variability between technical replicates within 
treatment groups. This was likely due to the poor quality of the extracted RNA and reagents used 
for treatments. Further analysis of A260/A230 ratios revealed poor RNA purity of Experiment 1 
extracted RNA. Prior to performing Experiment 2 with new cells, several adjustments were made 
to improve experimental conditions. In order to improve the quality and purity of the extracted 
RNA, the extraction was performed with smaller batches of cells at a time to prevent 
thawing/degradation that would disturb expression patterns. RNA was also eluted using spin 
columns to improve purity and yield for extraction. RNAase free micro-volume tubes were also 
used in place of standard micro-volume tubes during cDNA synthesis. New reagents were 
purchased for norepinephrine, 8-Br-cAMP, and glucagon treatments prior to the second 
experiment to replace expired reagents used for the first experiment. 
 
4.2 Hormone treatment effects on gene expression 
 The main objective of this study was to validate the findings of a previous experiment in 
our lab that suggested a possible role for ACSL4 in beta adrenergic signaling. While Experiment 
2 was conducted using higher quality RNA resulting in less apparent variability, the hormone 
treatments did not induce the gene expression patterns that were expected in control hepatocytes. 
All hormone treatments used for this study should have induced a similar response in control 
cells by raising intracellular levels of cAMP. Subsequent PKA activation results in CREB 
phosphorylation and downstream induction of PGC1a to upregulate genes associated with fatty 
acid oxidation and gluconeogenesis. Norepinephrine interacts with beta adrenergic GPCRs and 
causes the alpha subunit to activate adenylyl cyclase to convert ATP to cAMP. Glucagon works 
similarly to increase cAMP production by interacting with a different GPCR. Forskolin directly 
interacts with adenylyl cyclase at its catalytic domain to increase cAMP production. 8-Br-cAMP 
is a lipophilic synthetic analog that can enter cells, is resistant to cellular phosphodiesterases, and 
can directly activate PKA.  
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While all of these hormones have different mechanisms of action, they were expected to 
elicit similar increases in the expression of fatty acid oxidation genes in control hepatocytes. Not 
only did all of the treatments have inconsistent effects on increasing fatty acid oxidation gene 
expression, norepinephrine treatment actually caused a decrease in Cpt1a and Ppara expression 
in control hepatocytes. The Acsl4 L -/- hepatocytes did exhibit different expression patterns 
compared to control, however results were inconclusive due to the inconsistent effects observed 
in the control samples. Overall, the hormone treatments did not produce the anticipated effects 
and did not validate the findings of our previous study. Because of this, we were unable to form 
conclusions about whether the liver specific ACSL4 knockout decreased beta adrenergic 
signaling or other exogenous mechanisms of FA oxidation gene regulation.   
     
4.3 Fatty acid treatment effects on gene expression 
 This study also explored the role of fatty acids as intracellular signaling molecules to 
modulate fatty acid oxidation. Oleate increases intracellular levels of cAMP and expression of 
fatty acid oxidation genes in C2C12 myotube cells.14 While the mechanism behind how oleate 
elicits this cellular response is unknown, this finding illustrates the potential for therapeutic 
manipulation of intracellular lipid signaling to alter fatty acid oxidation through transcriptional 
regulation. Similar to the results from hormone treatment experiments, the gene expression 
changes following the lipid treatments in our study were not consistent with the findings of the 
published study. Oleate treatments were expected to increase expression of fatty acid oxidation 
genes while palmitate was not expected to affect expression. In control hepatocytes palmitate 
treatment increased gene expression of all genes of interest except Pgc-1a while oleate treatment 
only increased Creb expression. Similar to what was observed in the hormone treatment 
experiment, the ACSL4 knockout seemed to alter the cellular responses to treatments. Because 
the published study observed this signaling effect of oleate in C2C12 myotubes, it is possible that 
there may be a different effect in primary hepatocytes. This experiment must be repeated in order 
to draw conclusions on how different long chain fatty acids modulate fatty acid oxidation in 
hepatocytes and how the absence of ACSL4 alters this process.  
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4.4 Future Directions   
In an attempt to validate the findings of the previous study, most of the results from the 
hormone treatment experiment were inconclusive. Several steps can be taken to optimize 
treatment conditions to improve consistency of gene expression changes. Due to different 
mechanisms of action, each treatment could induce changes in gene expression at different rates. 
Time course experiments would allow us to optimize hormone treatment times for our study and 
better determine the effects of the ACSL4 knock out on gene expression. Concentration of the 
hormone treatments were based on the previous study and prior literature but could also be 
optimized in the context of our experiment. The efficacy of each treatment could also be 
validated by using immunoassays to measure intracellular cAMP concentrations. To further 
explore how each individual treatment or ACSL4 knockout affected gene expression, covalent 
modifications of CREB, PGC-1a, and SIRT-1 could be measured using western blot. We also 
plan to repeat the fatty acid treatment experiments to determine the role of fatty acid signaling in 
modulating gene expression in primary hepatocytes.  
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Figure 1. Lipid Treatments Gene Expression (Experiment 1) 
Relative gene expression (Actin) of Cpt1a, Creb, Acox1, Pgc1a, and Ppara in ACSL4 L -/- and 
WT hepatocytes following 3.5-hour oleate or palmitate treatment. 
 
Figure 2. Lipid Treatments Gene Expression (Experiment 2) 
Relative gene expression (Actin) of Cpt1a, Creb, Acox1, Pgc1a, and Ppara in ACSL4 L -/- and 
WT hepatocytes following 3.5-hour oleate or palmitate treatment. 
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Figure 3. Hormone Treatment Gene Expression (Experiment 1) 
Relative gene expression (Actin) of Pgc1a, Cpt1a, and Ppara following 1-hour (A) 
norepinephrine, (B) 8-Br-cAMP, and (C) forskolin treatments. Relative expression of Pepck, 
Pdk4, and G6pase following 1 hour (D) glucagon treatment 
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Figure 4. Hormone Treatment Gene Expression (Experiment 2) 
Relative gene expression (Actin) of Pgc1a, Cpt1a, and Ppara following 1-hour (A) 
norepinephrine, (B) 8-Br-cAMP, and (C) forskolin treatments. Relative expression of Pepck, 
Pdk4, and G6pase following 1-hour (D) glucagon treatment 
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Figure 5. Hormone Treatments and their Signaling Mechanisms 
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Treatment Vehicle Concentration  Time (Hr) 
Norepinephrine H2O 10µM 1 
8-Br-cAMP H2O 1mM 1 
Forskolin DMSO 40µM 1 
Glucagon PBS 100mM 1 
Oleate BSA 500µM 3.5 
Palmitate BSA 500µM 3.5 
 
Table 1. Treatment and Corresponding Vehicle Conditions 
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Target Direction Sequence 
Acsl4 
Forward ACAGCCTTGGAACCCGGGAGA 
Reverse CCCAATGCAGTGAGGCCACTTCC 
β-Actin 
Forward GGCTCCTAGCACCATGAAGA 
Reverse GAAAGGGTGTAAAACGCAGC 
Pgc-1α 
Forward CAACATGCTCAAGCCAAACCAACA 
Reverse CGCTCAATAGTCTTGTTCTCAAATGGG 
Pparα 
Forward CCTCAGGGTACCACTACGGAGTT 
Reverse TCGCCGAAAGAAGCCCTTA 
Cpt1a 
Forward CAACTATTATGCCATGGATTTTGTGCTT 
Reverse CGATACATGATCATGGCGTGAACG 
Creb 
Forward TCAGCCGGGTACTACCATTC 
Reverse TTCAGCAGGCTGTGTAGGAA 
Acox1 
Forward GGTGGACCTCTGTCTTGTTCA 
Reverse AAACCTTCAGGCCCAAGTGAG 
Pepck 
Forward TCAACACCGACCTCCCTTAC 
Reverse CATTGTGCCGCTATCTCAAA 
G6pase 
Forward TCTGTCCCGGATCTACCTTG 
Reverse TGGCAAAGGGTGTAGTGTCA 
Pdk4 
Forward CCGCTGTCCATGAAGCA 
Reverse GCAGAAAAGCAAAGGACGTT 
 
Table 2. RT-PCR Primer Sequences 	
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